218 related articles for article (PubMed ID: 24673480)
21. Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes.
Parikh KS; Fiuzat M; Davis G; Neely M; Blain-Nelson P; Whellan DJ; Abraham WT; Adams KF; Felker GM; Liggett SB; O'Connor CM; Bristow MR
Circ Genom Precis Med; 2018 Aug; 11(8):e002210. PubMed ID: 30354340
[TBL] [Abstract][Full Text] [Related]
22. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.
Lymperopoulos A; McCrink KA; Brill A
Curr Drug Metab; 2015; 17(1):30-6. PubMed ID: 26537419
[TBL] [Abstract][Full Text] [Related]
23. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
[TBL] [Abstract][Full Text] [Related]
24. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P
Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464
[TBL] [Abstract][Full Text] [Related]
25. Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Taniguchi T; Ohtani T; Mizote I; Kanzaki M; Ichibori Y; Minamiguchi H; Asano Y; Sakata Y; Komuro I
J Cardiol; 2013 Jun; 61(6):417-22. PubMed ID: 23548374
[TBL] [Abstract][Full Text] [Related]
26. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
[TBL] [Abstract][Full Text] [Related]
27. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
[TBL] [Abstract][Full Text] [Related]
28. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).
Torp-Pedersen C; Metra M; Charlesworth A; Spark P; Lukas MA; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Remme WJ; Scherhag A;
Heart; 2007 Aug; 93(8):968-73. PubMed ID: 17237130
[TBL] [Abstract][Full Text] [Related]
29. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
Lainscak M; Podbregar M; Kovacic D; Rozman J; von Haehling S
Respir Med; 2011 Oct; 105 Suppl 1():S44-9. PubMed ID: 22015086
[TBL] [Abstract][Full Text] [Related]
30. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
31. The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker.
Vardeny O; Detry MA; Moran JJ; Johnson MR; Sweitzer NK
J Cardiovasc Pharmacol; 2008 Dec; 52(6):500-6. PubMed ID: 19034036
[TBL] [Abstract][Full Text] [Related]
32. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
33. Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits.
Spaeder J; Najjar SS; Gerstenblith G; Hefter G; Kern L; Palmer JG; Gottlieb SH; Kasper EK
Am Heart J; 2006 Apr; 151(4):844.e1-10. PubMed ID: 16569544
[TBL] [Abstract][Full Text] [Related]
34. Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study.
Fröhlich H; Zhao J; Täger T; Cebola R; Schellberg D; Katus HA; Grundtvig M; Hole T; Atar D; Agewall S; Frankenstein L
Circ Heart Fail; 2015 Sep; 8(5):887-96. PubMed ID: 26175538
[TBL] [Abstract][Full Text] [Related]
35. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy.
Kumar A; Choudhary G; Antonio C; Just V; Jain A; Heaney L; Papp MA
Am Heart J; 2001 Sep; 142(3):512-5. PubMed ID: 11526366
[TBL] [Abstract][Full Text] [Related]
36. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
Ruwald MH; Ruwald AC; Jons C; Alexis J; McNitt S; Zareba W; Moss AJ
J Am Coll Cardiol; 2013 Apr; 61(14):1518-26. PubMed ID: 23500269
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
[TBL] [Abstract][Full Text] [Related]
38. Heart failure in a district general hospital: are target doses of beta-blockers realistic?
Mehta PA; McDonagh S; Poole-Wilson PA; Grocott-Mason R; Dubrey SW
QJM; 2004 Mar; 97(3):133-9. PubMed ID: 14976270
[TBL] [Abstract][Full Text] [Related]
39. Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol.
Troncoso R; Moraga F; Chiong M; Roldán J; Bravo R; Valenzuela R; Díaz-Araya G; del Campo A; Sanhueza C; Rodriguez A; Vukasovic JL; Mellado R; Greig D; Castro PF; Lavandero S
Basic Clin Pharmacol Toxicol; 2009 May; 104(5):374-8. PubMed ID: 19422106
[TBL] [Abstract][Full Text] [Related]
40. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
